Mycobacterium lepromatosis or Mycobacterium leprae causes leprosy and Hansen's disease (HD). A granulomatous disease, leprosy is the most common form of leprosy. Reddish lesions on the skin, loss of sensation, and muscle weakness are typical symptoms of leprosy. Muscle numbness is primarily caused by nerve damage. As a communicable disease, leprosy can be transmitted through contact with the cough or phlegm of an infected individual. The risk of leprosy is also increased by malnutrition and weakened immunity. Developing countries are particularly affected by leprosy.
In 2015, World Health Organization (WHO) statistics showed that the number of registered leprosy cases from various regions (138 countries) was 176,176, or 0.18 per 10 000 people. A sustained transmission of the disease is indicated by the number of new cases each year. Globally, 22 key countries accounted for 203,600 (96%) of the fresh leprosy cases. The high incidences of this disease around the world are a reminder that some regions of the world suffer from a high transmission rate. Over the last two decades, the World Health Organization has treated more than 16 million cases of leprosy. Globally, government agencies and governments are trying to eradicate the disease's presence. Over the forecast period (2016-2024), the leprosy treatment market is expected to grow at a substantial rate.
For many decades, mankind has been plagued by leprosy. The World Health Organization and various governments around the world needed to get involved in this process. The government plays a crucial role in the leprosy treatment market. Multidrug therapy has been adopted by governments around the world since 1982, when WHO introduced it. Some of them provided subsidies to eradicate the disease in their countries. Leprosy treatment market growth, therefore, is largely driven by government regulation and adoption.